Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.44 |
| ▸ | USP1 | O94782 | 6/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12759447 | 0.85 | NR1H3 (0.47) | PTGS2PTGS1NPC1RAB9ANR1H2 | |
| SCHEMBL11624763 | 0.84 | PTGS2 (0.42) | PTGS2PTGS1USP1 | |
| Ammonia Solution, Strong SCHEMBL29124929 | 0.84 | PTGS2 (0.52) | PTGS2PTGS1USP1 | |
| SCHEMBL10915635 | 0.83 | PTGS2 (0.44) | PTGS2PTGS1NPC1RAB9AUSP1 | |
| SCHEMBL29124933 | 0.83 | PTGS2 (0.41) | PTGS2PTGS1USP1 | |
| SCHEMBL25431072 | 0.83 | PTGS2 (0.44) | PTGS2PTGS1NPC1RAB9AUSP1 | |
| SCHEMBL22165856 | 0.83 | PTGS2 (0.44) | PTGS2PTGS1USP1 | |
| SCHEMBL11628555 | 0.83 | PTGS2 (0.56) | PTGS2PTGS1NR1H2NR1H3USP1 | |
| SCHEMBL11625962 | 0.82 | PTGS2 (0.60) | PTGS2USP1CYP1A2CYP2C19 | |
| SCHEMBL31138700 | 0.81 | PTGS2 (0.44) | PTGS2PTGS1USP1CYP2D6HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117425656-A | Purine derivatives as anticancer agents | 探戈医药股份有限公司 | 2024-01-19 | — | — | CN | disclosed |
| US-20150325802-A1 | ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG SDI CO., LTD., (KR) | 2015-11-12 | — | — | US | disclosed |
| US-20150325802-A1 | ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG SDI CO., LTD., (KR) | 2015-11-12 | — | — | US | disclosed |
| US-20080269344-A1 | Beta2-Adrenergic Receptor Agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-10-30 | — | — | US | disclosed |
| US-7427639-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-20070179179-A1 | Beta2-adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-08-02 | — | — | US | disclosed |
| US-7217738-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-7211695-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2007-05-01 | — | — | US | disclosed |
| CN-1153766-C | Nitroketone compound, its preparing process and pharmaceutical composition containing same | ɪά��ʵ���� | 2004-06-16 | — | — | CN | disclosed |
| EP-0967207-B1 | Nitrone derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2002-09-11 | — | — | EP | disclosed |
| CN-1245169-A | Nitroketone compound, its preparing process and pharmaceutical composition containing same | ADIR (FR) | 2000-02-23 | — | — | CN | disclosed |
| EP-0967207-A1 | Nitrone derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1999-12-29 | — | — | EP | disclosed |
| US-4125530-A | FROM 1,1-DIHALO-3,3,3-TRIFLUOROACETONE, BASE, AMMONIA AND A CARBOXALDEHYDE | MERCK & CO., INC. (US) | 1978-11-14 | — | — | US | disclosed |
| US-4032522-A | ANTI-GOUT, ANTI-HYPERURICEMIC | MERCK & CO., INC. (US) | 1977-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150325802-A1 | ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CHRM1, CRY1, FOXM1 | PTGS2 1519/4885PTGS1 772/4885NPC1 4003/4885 |
| US-20080269344-A1 | Beta2-Adrenergic Receptor Agonists | ADRB2, ADRB1, ADRA2B | PTGS2 262/4885PTGS1 520/4885NPC1 2718/4885 |
| US-20070179179-A1 | Beta2-adrenergic receptor agonists | ADRB2, ADRB1, ADRA2B | PTGS2 262/4885PTGS1 520/4885NPC1 2718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.